Anti-angiogenic agents in metastatic colorectal cancer

World Journal of Gastrointestinal Oncology

Volumn 7, Issue 7, 2015, Pages 71-86

  Konda, Bhavana ^a   Shum, Helen ^a   Rajdev, Lakshmi ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Anti angiogenic agents; cancer; Colorectal; Conversion therapy; metastasectomy; Metastatic colorectal; Targeted agents

Indexed keywords

EID: 85016252135     PISSN: None     EISSN: 19485204     Source Type: Journal    
DOI: 10.4251/wjgo.v7.i7.71     Document Type: Article

References (119)

1. 1 Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29 [PMID: 24399786 DOI: 10.3322/caac.21208]
2. 2 Wicherts DA, de Haas RJ, Adam R. Bringing unresectable liver disease to resection with curative intent. Eur J Surg Oncol 2007; 33 Suppl 2: S42-S51 [PMID: 17981429 DOI: 10.1016/j.ejso.2007.09.017]
3. 3 Klinger M, Tamandl D, Eipeldauer S, Hacker S, Herberger B, Kaczirek K, Dorfmeister M, Gruenberger B, Gruenberger T. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol 2010; 17: 2059-2065 [PMID: 20177795 DOI: 10.1245/s10434-010-0972-9]
4. 4 Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E, Scheiner J. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957; 179: 663-666 [PMID: 13418758]
5. 5 Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186 [PMID: 4938153 DOI: 10.1056/ NEJM197111182852108]
6. 6 Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31 [PMID: 7584949]
7. 7 Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-10934 [PMID: 1375931]
8. 8 Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002; 2: 826-835 [PMID: 12415253 DOI: 10.1038/nrc925]
9. 9 Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-1027 [PMID: 15585754 DOI: 10.1200/jco.2005.06.081]
10. 10 Holmes DI, Zachary I. The vascular endothelial growth factor(VEGF) family: angiogenic factors in health and disease. Genome Biol 2005; 6: 209 [PMID: 15693956 DOI: 10.1186/gb-2005-6-2-209]
11. 11 Lee JJ, Chu E. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2014; 13: 135-144 [PMID: 24768040 DOI: 10.1016/j.clcc.2014.02.001]
12. 12 Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985 [PMID: 6823562]
13. 13 Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25 [PMID: 9034784 DOI: 10.1210/edrv.18.1.0287]
14. 14 Dimova I, Popivanov G, Djonov V. Angiogenesis in cancer - general pathways and their therapeutic implications. J BUON 2014; 19:15-21 [PMID: 24659637]
15. 15 Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer 2013; 13: 871-882 [PMID: 24263190 DOI: 10.1038/nrc3627]
16. 16 Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-1039 [PMID: 7538264]
17. 17 Gacche RN, Meshram RJ. Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy. Biochim Biophys Acta 2014; 1846: 161-179 [PMID: 24836679 DOI: 10.1016/ j.bbcan.2014.05.002]
18. 18 Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH, Zopf D. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011; 129: 245-255 [PMID: 21170960 DOI: 10.1002/ ijc.25864]
19. 19 Abdollahi A, Lipson KE, Sckell A, Zieher H, Klenke F, Poerschke D, Roth A, Han X, Krix M, Bischof M, Hahnfeldt P, Grone HJ, Debus J, Hlatky L, Huber PE. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 2003; 63: 8890-8898 [PMID: 14695206]
20. 20 Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-4599 [PMID: 9377574]
21. 21 Elamin YY, Rafee S, Toomey S, Hennessy BT. Immune effects of bevacizumab: killing two birds with one stone. Cancer Microenviron 2015; 8: 15-21 [PMID: 25326055 DOI: 10.1007/s12307-014-0160-8]
22. 22 Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342 [PMID: 15175435 DOI:10.1056/NEJMoa032691]
23. 23 Hurwitz HI, Tebbutt NC, Kabbinavar F, Giantonio BJ, Guan ZZ, Mitchell L, Waterkamp D, Tabernero J. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist 2013; 18: 1004-1012 [PMID: 23881988 DOI: 10.1634/theoncologist.2013-0107]
24. 24 Cartwright TH. Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management. Clin Colorectal Cancer 2013; 12: 86-94 [PMID: 23562587 DOI: 10.1016/j.clcc.2012.12.001]
25. 25 Higa GM, Abraham J. Biological mechanisms of bevacizumabassociated adverse events. Expert Rev Anticancer Ther 2009; 9: 999-1007 [PMID: 19589038 DOI: 10.1586/era.09.68]
26. 26 Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65 [PMID: 12506171]
27. 27 Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697-3705 [PMID: 15738537 DOI: 10.1200/ jco.2005.05.112]
28. 28 Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: 3706-3712 [PMID: 15867200 DOI: 10.1200/JCO.2005.00.232]
29. 29 Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019
30. 30 Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Maspero F, Sauta MG, Beretta GD, Barni S. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. Clin Colorectal Cancer 2013; 12: 145-151 [PMID: 23763824 DOI: 10.1016/j.clcc.2013.04.006]
31. 31 Sobrero AF, Young S, Balcewicz M, Chiarra S, Perez Carrion R, Mainwaring P, Gapski J, Clarke S, Langer B, Ackland S. Phase IV study of first-line bevacizumab plus irinotecan and infusional 5-FU/LV in patients with metastatic colorectal cancer: AVIRI. ASCO Meeting Abstracts 2007; 25 (18_suppl): 4068
32. 32 Pectasides D, Papaxoinis G, Kalogeras KT, Eleftheraki AG, Xanthakis I, Makatsoris T, Samantas E, Varthalitis I, Papakostas P, Nikitas N, Papandreou CN, Pentheroudakis G, Timotheadou E, Koutras A, Sgouros J, Bafaloukos D, Klouvas G, Economopoulos T, Syrigos KN, Fountzilas G. XELIRI-bevacizumab versus FOLFIRIbevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. BMC Cancer 2012; 12: 271 [PMID: 22748098 DOI: 10.1186/1471-2407-12-271]
33. 33 Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676 [PMID: 17470860 DOI: 10.1200/jco.2006.09.0928]
34. 34 Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014; 371: 1609-1618 [PMID: 25337750 DOI: 10.1056/NEJMoa1403108]
35. 35 Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, Wong L, Fehrenbacher L, Abubakr Y, Saif MW, Schwartzberg L, Hedrick E. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008; 26: 3523-3529 [PMID: 18640933 DOI: 10.1200/ JCO.2007.15.4138]
36. 36 Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling- Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1065-1075 [PMID: 25088940 DOI:10.1016/s1470-2045(14)70330-4]
37. 37 Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Mahoney MR, O’Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Mayer RJ, Schilsky RL, Bertagnolli MM, Blanke CD; Cancer, Leukemia Group B S, ECOG. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5- FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). ASCO Meeting Abstracts 2014; 32 (18_suppl): LBA3
38. 38 Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martínez de Prado P, Gallén M, González E, Marcuello E, Benavides M, Fernández-Martos C, Losa F, Escudero P, Arrivi A, Cervantes A, Dueñas R, López-Ladrón A, Lacasta A, Llanos M, Tabernero JM, Antón A, Aranda E. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 2012; 17: 15-25 [PMID: 22234633 DOI: 10.1634/ theoncologist.2011-0249]
39. 39 Moscetti L, Nelli F, Fabbri MA, Sperduti I, Alesini D, Cortesi E, Gemma D, Gamucci T, Grande R, Pavese I, Franco D, Ruggeri EM. Maintenance single-agent bevacizumab or observation after firstline chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study. Invest New Drugs 2013; 31: 1035-1043 [PMID: 23417697 DOI: 10.1007/s10637-013-9936-9]
40. 40 Koopman M, Simkens L, May AM, Mol L, van Tinteren H, Punt CJA. Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine bevacizumab versus observation after induction treatment with chemotherapy bevacizumab in metastatic colorectal cancer (mCRC). ASCO Meeting Abstracts 2014; 32 (15_suppl): 3504
41. 41 Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544 [PMID: 17442997 DOI: 10.1200/ JCO.2006.09.6305]
42. 42 Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26: 5326-5334 [PMID: 18854571 DOI: 10.1200/jco.2008.16.3212]
43. 43 Giantonio BJ. Targeted therapies: Goldie-Coldman and bevacizumab beyond disease progression. Nat Rev Clin Oncol 2009; 6: 311-312 [PMID: 19483736 DOI: 10.1038/nrclinonc.2009.66]
44. 44 Grothey A, Flick ED, Cohn AL, Bekaii-Saab TS, Bendell JC, Kozloff M, Roach N, Mun Y, Fish S, Hurwitz HI. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiol Drug Saf 2014; 23: 726-734 [PMID: 24830357 DOI: 10.1002/pds.3633]
45. 45 Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso- Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14: 29-37 [PMID: 23168366 DOI: 10.1016/ s1470-2045(12)70477-1]
46. 46 Masi G, Salvatore L, Boni L, Loupakis F, Cremolini C, Fornaro L, Schirripa M, Cupini S, Barbara C, Safina V, Granetto C, Fea E, Antonuzzo L, Boni C, Allegrini G, Chiara S, Amoroso D, Bonetti A, Falcone A. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann Oncol 2015; 26: 724-730 [PMID: 25600568 DOI: 10.1093/annonc/mdv012]
47. 47 Kozloff MF, Berlin J, Flynn PJ, Kabbinavar F, Ashby M, Dong W, Sing AP, Grothey A. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology 2010; 78: 329-339 [PMID: 20733336 DOI: 10.1159/000320222]
48. 48 Hofheinz R, Petersen V, Kindler M, Schulze M, Seraphin J, Hoeffkes HG, Valdix AR, Schroeder J, Herrenberger J, Stein A, Hinke A, Arnold D. Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German communitybased observational cohort study results. BMC Cancer 2014; 14: 761 [PMID: 25311943 DOI: 10.1186/1471-2407-14-761]
49. 49 Vamvakas L, Matikas A, Karampeazis A, Hatzidaki D, Kakolyris S, Christophylakis C, Boukovinas I, Polyzos A, Georgoulias V, Souglakos J. Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged & gt; 70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG). BMC Cancer 2014; 14: 277 [PMID: 24755296 DOI: 10.1186/1471-2407-14-277]
50. 50 Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 2009; 27: 199-205 [PMID: 19064978 DOI: 10.1200/jco.2008.17.7931]
51. 51 Cassidy J, Saltz LB, Giantonio BJ, Kabbinavar FF, Hurwitz HI, Rohr UP. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol 2010; 136: 737-743 [PMID: 19904559 DOI: 10.1007/s00432-009-0712-3]
52. 52 Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, Saunders MP. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013; 14: 1077-1085 [PMID: 24028813 DOI: 10.1016/ S1470-2045(13)70154-2]
53. 53 Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, RussellM, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, HuangT, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ,Yancopoulos GD, Rudge JS. VEGF-Trap: a VEGF blocker withpotent antitumor effects. Proc Natl Acad Sci USA 2002; 99:11393-11398 [PMID: 12177445 DOI: 10.1073/pnas.172398299]
54. 54 Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012; 15: 171-185 [PMID: 22302382 DOI: 10.1007/ s10456-011-9249-6]
55. 55 Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, Buzenet G, Koehler E, Sosman JA, Schwartz LH, Gultekin DH, Koutcher JA, Donnelly EF, Andal R, Dancy I, Spriggs DR, Tew WP. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 2010; 28: 207-214 [PMID: 19949018 DOI: 10.1200/jco.2009.22.9237]
56. 56 Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012; 30: 3499-3506 [PMID: 22949147 DOI: 10.1200/jco.2012.42.8201]
57. 57 Tang PA, Cohen SJ, Kollmannsberger C, Bjarnason G, Virik K, MacKenzie MJ, Lourenco L, Wang L, Chen A, Moore MJ. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. Clin Cancer Res 2012; 18: 6023-6031 [PMID: 22977191 DOI: 10.1158/1078-0432. ccr-11-3252]
58. 58 Chau I, Joulain F, Iqbal SU, Bridgewater J. A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. BMC Cancer 2014; 14: 605 [PMID: 25142418 DOI: 10.1186/1471-2407-14-605]
59. 59 Tabchi S, Ghosn M. Regorafenib: start low and go slow. Target Oncol 2014; Epub ahead of print [PMID: 25548130 DOI: 10.1007 s11523-014-0352-7]
60. 60 Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U, Unger C, Krätzschmar J, Heinig R, Boix O, Christensen O. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 2012; 18: 2658-2667 [PMID: 22421192 DOI: 10.1158/1078-0432.ccr-11-1900]
61. 61 Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Büchert M, Christensen O, Jeffers M, Heinig R, Boix O, Mross K. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer 2012; 106: 1722-1727 [PMID: 22568966 DOI: 10.1038/bjc.2012.153]
62. 62 Schultheis B, Folprecht G, Kuhlmann J, Ehrenberg R, Hacker UT, Köhne CH, Kornacker M, Boix O, Lettieri J, Krauss J, Fischer R, Hamann S, Strumberg D, Mross KB. Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Ann Oncol 2013; 24: 1560-1567 [PMID: 23493136 DOI: 10.1093/annonc/ mdt056]
63. 63 Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303-312 [PMID: 23177514 DOI: 10.1016/s0140- 6736(12)61900-x]
64. 64 Spratlin JL, Mulder KE, Mackey JR. Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncol 2010; 6: 1085-1094 [PMID: 20624120 DOI: 10.2217/fon.10.75]
65. 65 Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O’Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010; 28: 780-787 [PMID: 20048182 DOI: 10.1200/ jco.2009.23.7537]
66. 66 Garcia-Carbonero R, Rivera F, Maurel J, Ayoub JP, Moore MJ, Cervantes A, Asmis TR, Schwartz JD, Nasroulah F, Ballal S, Tabernero J. An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as firstline therapy for metastatic colorectal cancer. Oncologist 2014; 19: 350-351 [PMID: 24674871 DOI: 10.1634/theoncologist.2014-0028]
67. 67 Tabernero J, Cohn AL, Obermannova R, Bodoky G, Garcia- Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Zagonel V, Kim TW, Simms L, Chang SC, Nasroulah F, Yoshino T, Investigators TRS. RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp). ASCO Meeting Abstracts 2015; 33 (suppl_3): 512
68. 68 Xu RH, Shen L, Wang K, Wu G, Shi C, Ding K, Lin L, Wang J, Xiong J, Wu C, Li J, Liu Y, Wang D, Ba Y, Feng J, Bai Y, Bi J, MA L, Lei J, Yu H. A randomized, double-blind, parallel-group, placebocontrolled, multicenter, phase II clinical study of famitinib in the treatment of advanced metastatic colorectal cancer. ASCO Meeting Abstracts 2015; 33 (3_suppl): 513
69. 69 Zhou A, Zhang W, Chang C, Chen X, Zhong D, Qin Q, Lou D, Jiang H, Wang J. Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib. Cancer Chemother Pharmacol 2013; 72: 1043-1053 [PMID: 24043137 DOI: 10.1007/s00280-013- 2282-y]
70. 70 Xie C, Zhou J, Guo Z, Diao X, Gao Z, Zhong D, Jiang H, Zhang L, Chen X. Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol 2013; 168: 1687-1706 [PMID: 23126373 DOI: 10.1111/bph.12047]
71. 71 Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, Evangelisti C, Cocco L, Martelli AM, McCubrey JA. Ras/ Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011; 2: 135-164 [PMID: 21411864]
72. 72 Di Marco V, De Vita F, Koskinas J, Semela D, Toniutto P, Verslype C. Sorafenib: from literature to clinical practice. Ann Oncol 2013; 24 Suppl 2: ii30-ii37 [PMID: 23715941 DOI: 10.1093/annonc/mdt055]
73. 73 Samalin E, Bouché O, Thézenas S, Francois E, Adenis A, Bennouna J, Taieb J, Desseigne F, Seitz JF, Conroy T, Galais MP, Assenat E, Crapez E, Poujol S, Bibeau F, Boissière F, Laurent-Puig P, Ychou M, Mazard T. Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRASmutated tumours: a multicentre Phase I/II trial. Br J Cancer 2014; 110: 1148-1154 [PMID: 24407191 DOI: 10.1038/bjc.2013.813]
74. 74 Tabernero J, Garcia-Carbonero R, Cassidy J, Sobrero A, Van Cutsem E, Köhne CH, Tejpar S, Gladkov O, Davidenko I, Salazar R, Vladimirova L, Cheporov S, Burdaeva O, Rivera F, Samuel L, Bulavina I, Potter V, Chang YL, Lokker NA, O’Dwyer PJ. Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. Clin Cancer Res 2013; 19: 2541-2550 [PMID: 23532888 DOI: 10.1158/1078-0432.ccr-13-0107]
75. 75 Tsuji Y, Satoh T, Tsuji A, Muro K, Yoshida M, Nishina T, Nagase M, Komatsu Y, Kato T, Miyata Y, Mizutani N, Hashigaki S, Lechuga MJ, Denda T. First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study. Cancer Sci 2012; 103: 1502-1507 [PMID: 22537162 DOI: 10.1111/ j.1349-7006.2012.02320.x]
76. 76 Heng DY, Kollmannsberger C. Sunitinib. Recent Results Cancer Res 2010; 184: 71-82 [PMID: 20072832 DOI: 10.1007/978-3-642-0 1222-8_6]
77. 77 Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62: 4645-4655 [PMID: 12183421]
78. 78 Vozniak JM, Jacobs JM. Vandetanib. J Adv Pract Oncol 2012; 3: 112-116 [PMID: 25031937]
79. 79 Michael M, Gibbs P, Smith R, Godwood A, Oliver S, Tebbutt N. Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer. Invest New Drugs 2009; 27: 253-261 [PMID: 19002384 DOI: 10.1007/ s10637-008-9182-8]
80. 80 Saunders MP, Wilson R, Peeters M, Smith R, Godwood A, Oliver S, Van Cutsem E. Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study. Cancer Chemother Pharmacol 2009; 64: 665-672 [PMID: 19184020 DOI: 10.1007/s00280-008-0914-4]
81. 81 Yang TS, Oh DY, Guimbaud R, Szanto J, Salek T, Thurzo L, Vieitez JM, Pover GM, Kim TW. Vandetanib plus mFOLFOX6 in patients with advanced colorectal cancer (CRC): A randomized, doubleblind, placebo-controlled phase II study. ASCO Meeting Abstracts 2009; 27 (15S): 4084
82. 82 Hess-Stumpp H, Haberey M, Thierauch KH. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy. Chembiochem 2005; 6: 550-557 [PMID: 15742376 DOI: 10.1002/cbic.200400305]
83. 83 Thomas AL, Morgan B, Drevs J, Unger C, Wiedenmann B, Vanhoefer U, Laurent D, Dugan M, Steward WP. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin Oncol 2003; 30: 32-38 [PMID: 12802793]
84. 84 Van Cutsem E, Bajetta E, Valle J, Köhne CH, Hecht JR, Moore M, Germond C, Berg W, Chen BL, Jalava T, Lebwohl D, Meinhardt G, Laurent D, Lin E. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 2011; 29: 2004-2010 [PMID: 21464401 DOI: 10.1200/jco.2010.29.5436]
85. 85 Hecht JR, Trarbach T, Hainsworth JD, Major P, Jäger E, Wolff RA, Lloyd-Salvant K, Bodoky G, Pendergrass K, Berg W, Chen BL, Jalava T, Meinhardt G, Laurent D, Lebwohl D, Kerr D. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 2011; 29: 1997-2003 [PMID: 21464406 DOI: 10.1200/jco.2010.29.4496]
86. 86 Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27: 3677-3683 [PMID: 19470929 DOI: 10.1200/jco.2008.20.5278]
87. 87 Viganò L, Russolillo N, Ferrero A, Langella S, Sperti E, Capussotti L. Evolution of long-term outcome of liver resection for colorectal metastases: analysis of actual 5-year survival rates over two decades. Ann Surg Oncol 2012; 19: 2035-2044 [PMID: 22219066 DOI: 10.1245/s10434-011-2186-1]
88. 88 Wicherts DA, de Haas RJ, Andreani P, Ariche A, Salloum C, Pascal G, Castaing D, Adam R, Azoulay D. Short- and long-term results of extended left hepatectomy for colorectal metastases. HPB (Oxford) 2011; 13: 536-543 [PMID: 21762296 DOI: 10.1111/ j.1477-2574.2011.00321.x]
89. 89 Adam R, Wicherts DA, de Haas RJ, Ciacio O, Lévi F, Paule B, Ducreux M, Azoulay D, Bismuth H, Castaing D. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 2009; 27: 1829-1835 [PMID: 19273699 DOI: 10.1200/jco.2008.19.9273]
90. 90 Van Cutsem E, Nordlinger B, Adam R, Köhne CH, Pozzo C, Poston G, Ychou M, Rougier P. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006; 42: 2212-2221 [PMID: 16904315 DOI: 10.1016/ j.ejca.2006.04.012]
91. 91 Blackmon SH, Stephens EH, Correa AM, Hofstetter W, Kim MP, Mehran RJ, Rice DC, Roth JA, Swisher SG, Walsh GL, Vaporciyan AA. Predictors of recurrent pulmonary metastases and survival after pulmonary metastasectomy for colorectal cancer. Ann Thorac Surg 2012; 94: 1802-1809 [PMID: 23063195 DOI: 10.1016/j.athoracsur.2 012.07.014]
92. 92 Cho JH, Hamaji M, Allen MS, Cassivi SD, Nichols FC, Wigle DA, Shen KR, Deschamps C. The prognosis of pulmonary metastasectomy depends on the location of the primary colorectal cancer. Ann Thorac Surg 2014; 98: 1231-1237 [PMID: 25086943 DOI: 10.1016/j.athoracsur.2014.05.023]
93. 93 Gonzalez M, Robert JH, Halkic N, Mentha G, Roth A, Perneger T, Ris HB, Gervaz P. Survival after lung metastasectomy in colorectal cancer patients with previously resected liver metastases. World J Surg 2012; 36: 386-391 [PMID: 22167262 DOI: 10.1007/ s00268-011-1381-3]
94. 94 Shah SA, Haddad R, Al-Sukhni W, Kim RD, Greig PD, Grant DR, Taylor BR, Langer B, Gallinger S, Wei AC. Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg 2006; 202: 468-475 [PMID: 16500252 DOI: 10.1016/ j.jamcollsurg.2005.11.008]
95. 95 Bertolini F, Malavasi N, Scarabelli L, Fiocchi F, Bagni B, Del Giovane C, Colucci G, Gerunda GE, Depenni R, Zironi S, Fontana A, Pettorelli E, Luppi G, Conte PF. FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. Br J Cancer 2011; 104: 1079-1084 [PMID: 21386839 DOI: 10.1038/ bjc.2011.43]
96. 96 Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, Gruenberger T. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26: 1830-1835 [PMID: 18398148 DOI: 10.1200/jco.2007.13.7679]
97. 97 Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T, Mudan S, Brown G, Khan A, Wotherspoon A, Strimpakos AS, Thomas J, Compton S, Chua YJ, Chau I. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 2011; 22: 2042-2048 [PMID: 21285134 DOI: 10.1093/annonc/mdq714]
98. 98 Loupakis F, Schirripa M, Caparello C, Funel N, Pollina L, Vasile E, Cremolini C, Salvatore L, Morvillo M, Antoniotti C, Marmorino F, Masi G, Falcone A. Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. Br J Cancer 2013; 108: 2549-2556 [PMID: 23703247 DOI: 10.1038/bjc.2013.245]
99. 99 Nasti G, Piccirillo MC, Izzo F, Ottaiano A, Albino V, Delrio P, Romano C, Giordano P, Lastoria S, Caracò C, de Lutio di Castelguidone E, Palaia R, Daniele G, Aloj L, Romano G, Iaffaioli RV. Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial. Br J Cancer 2013; 108: 1566-1570 [PMID: 23558891 DOI: 10.1038/ bjc.2013.140]
100. 100 Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A, Del Monte F, Cortesi E, Amoroso D, Granetto C, Fontanini G, Sensi E, Lupi C, Andreuccetti M, Falcone A. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010; 11: 845-852 [PMID: 20702138 DOI: 10.1016/ s1470-2045(10)70175-3]
101. 101 Osterlund P, Peltonen R, Alanko T, Bono P, Isoniemi H. A singleinstitution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection. Onco Targets Ther 2014; 7: 1177-1184 [PMID: 25061319 DOI: 10.2147/ott.s63739]
102. 102 Gruenberger T, Bridgewater J, Chau I, García Alfonso P, Rivoire M, Mudan S, Lasserre S, Hermann F, Waterkamp D, Adam R. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol 2015; 26: 702-708 [PMID: 25538173 DOI: 10.1093/annonc/mdu580]
103. 103 Dede K, Mersich T, Besznyák I, Zaránd A, Salamon F, Baranyai ZS, Landherr L, Jakab F, Bursics A. Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment. Pathol Oncol Res 2013; 19: 501-508 [PMID: 23420304 DOI: 10.1007/s12253-013-9608-2]
104. 104 Cvetanovic A, Vrbic S, Filipovic S, Pejcic I, Milenkovic D, Milenkovic N, Zivkovic N. Safety and efficacy of addition of bevacizumab to oxaliplatin-based preoperative chemotherapy in colorectal cancer with liver metastasis- a single institution experience. J BUON 2013; 18: 641-646 [PMID: 24065477]
105. 105 Lubezky N, Winograd E, Papoulas M, Lahat G, Shacham-Shmueli E, Geva R, Nakache R, Klausner J, Ben-Haim M. Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases. J Gastrointest Surg 2013; 17: 527-532 [PMID: 23299220 DOI: 10.1007/s11605-012- 2108-y]
106. 106 Millet G, Truant S, Leteurtre E, Hebbar M, Zerbib P, Huet G, Boleslawski E, Pruvot FR. Volumetric analysis of remnant liver regeneration after major hepatectomy in bevacizumab-treated patients: a case-matched study in 82 patients. Ann Surg 2012; 256: 755-761; discussion 761-762 [PMID: 23095619 DOI: 10.1097/ SLA.0b013e31827381ca]
107. 107 Starlinger P, Alidzanovic L, Schauer D, Maier T, Nemeth C, Perisanidis B, Tamandl D, Gruenberger B, Gruenberger T, Brostjan C. Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation. Br J Cancer 2012; 107: 961-966 [PMID: 22850548 DOI: 10.1038/bjc.2012.342]
108. 108 Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey JN, Rodriguez-Bigas MA, Curley SA, Feig BW. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 2008; 26: 5254-5260 [PMID: 18854565 DOI: 10.1200/jco.2008.17.7857]
109. 109 Constantinidou A, Cunningham D, Shurmahi F, Asghar U, Barbachano Y, Khan A, Mudan S, Rao S, Chau I. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection. Clin Colorectal Cancer 2013; 12: 15-22 [PMID: 23021126 DOI: 10.1016/j.clcc.2012.07.002]
110. 110 Kitamura H, Koike S, Nakazawa K, Matsumura H, Yokoi K, Nakagawa K, Arai M. A reversal in the vascularity of metastatic liver tumors from colorectal cancer after the cessation of chemotherapy plus bevacizumab: contrast-enhanced ultrasonography and histological examination. J Surg Oncol 2013; 107: 155-159 [PMID: 22903532 DOI: 10.1002/jso.23244]
111. 111 Reddy SK, Morse MA, Hurwitz HI, Bendell JC, Gan TJ, Hill SE, Clary BM. Addition of bevacizumab to irinotecan- and oxaliplatinbased preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008; 206: 96-106 [PMID: 18155574 DOI: 10.1016/j.jamcolls urg.2007.06.290]
112. 112 van der Pool AE, Marsman HA, Verheij J, Ten Kate FJ, Eggermont AM, Ijzermans JN, Verhoef C. Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases. J Surg Oncol 2012; 106: 892-897 [PMID: 22552819 DOI: 10.1002/jso.23142]
113. 113 Rubbia-Brandt L, Lauwers GY, Wang H, Majno PE, Tanabe K, Zhu AX, Brezault C, Soubrane O, Abdalla EK, Vauthey JN, Mentha G, Terris B. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010; 56: 430-439 [PMID: 20459550 DOI: 10.1111/j.1365-2559.2010.03511.x]
114. 114 Turan N, Benekli M, Koca D, Ustaalioglu BO, Dane F, Ozdemir N, Ulas A, Oztop I, Gumus M, Ozturk MA, Berk V, Kucukoner M, Uner A, Balakan O, Helvaci K, Ozkan S, Yilmaz U, Buyukberber S. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer. Oncology 2013; 84: 14-21 [PMID: 23076023 DOI: 10.1159/000342429]
115. 115 Stathopoulos GP, Batziou C, Trafalis D, Koutantos J, Batzios S, Stathopoulos J, Legakis J, Armakolas A. Treatment of colorectal cancer with and without bevacizumab: a phase III study. Oncology 2010; 78: 376-381 [PMID: 20798560 DOI: 10.1159/000320520]
116. 116 Starling N, Vázquez-Mazón F, Cunningham D, Chau I, Tabernero J, Ramos FJ, Iveson TJ, Saunders MP, Aranda E, Countouriotis AM, Ruiz-Garcia A, Wei G, Tursi JM, Guillen-Ponce C, Carrato A. A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. Ann Oncol 2012; 23: 119-127 [PMID: 21447616 DOI: 10.1093/annonc/mdr046]
117. 117 Yoshino T, Yamazaki K, Hamaguchi T, Shimada Y, Kato K, Yasui H, Boku N, Lechuga MJ, Hirohashi T, Shibata A, Hashigaki S, Li Y, Ohtsu A. Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer. Anticancer Res 2012; 32: 973-979 [PMID: 22399619]
118. 118 Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 2007; 25: 4793-4799 [PMID: 17947727 DOI: 10.1200/jco.2007.12.8637]
119. 119 Carrato A, Swieboda-Sadlej A, Staszewska-Skurczynska M, Lim R, Roman L, Shparyk Y, Bondarenko I, Jonker DJ, Sun Y, De la Cruz JA, Williams JA, Korytowsky B, Christensen JG, Lin X, Tursi JM, Lechuga MJ, Van Cutsem E. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. J Clin Oncol 2013; 31: 1341-1347 [PMID: 23358972 DOI: 10.1200/jco.2012.45.1930]